OSE Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 3/6
OSE Immunotherapeutics has a total shareholder equity of €32.7M and total debt of €40.3M, which brings its debt-to-equity ratio to 123.5%. Its total assets and total liabilities are €91.8M and €59.1M respectively.
Key information
123.5%
Debt to equity ratio
€40.32m
Debt
Interest coverage ratio | n/a |
Cash | €25.62m |
Equity | €32.66m |
Total liabilities | €59.12m |
Total assets | €91.78m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: OSEP's short term assets (€37.2M) exceed its short term liabilities (€16.3M).
Long Term Liabilities: OSEP's short term assets (€37.2M) do not cover its long term liabilities (€42.9M).
Debt to Equity History and Analysis
Debt Level: OSEP's net debt to equity ratio (45%) is considered high.
Reducing Debt: OSEP's debt to equity ratio has increased from 8.8% to 123.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSEP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OSEP is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.